Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase?

• Main Authors: Maria Cristina Campopiano, Antonio Matrone, Teresa Rago, Maria Scutari, Alessandro Prete, Laura Agate, Paolo Piaggi, Rossella Elisei, Eleonora Molinaro
• Format: Article
• Language: English
• Published: MDPI AG 2021-09-01
• Series: Journal of Clinical Medicine
• Subjects: differentiated thyroid cancer; papillary thyroid microcarcinoma; active surveillance; management; observation; tailored treatment for thyroid cancer
• Online Access: https://www.mdpi.com/2077-0383/10/18/4068

Active surveillance (AS) is considered an alternative to immediate surgery in micropapillary thyroid carcinoma (mPTC). However, the definition of clinical mPTC progression during AS is controversial. We evaluated changes in tumor size using both tumor diameters and volume in 109 patients with mPTC followed in an AS protocol for a mean period of 31 ± 18 months. At the time of data lock, 19/109 (17.4%) mPTC reached and maintained a volume increase of ≥50%. However, only 3/19 (15.7%) showed progression, according to the diameter increase. The remaining 16 showed a slight diameter growth without reaching the original protocol progression criteria. The mean mPTC growth rate in stable cases was 0.37 mm³/month, while it was significantly greater in the mPTC, which achieved a volume change ≥50% with respect to the other. The two mPTC that developed a significant diameter increase had a growth rate of 41 and 18 mm³/month. Instead, the growth rates of the three mPTC that developed lymph node metastases were 0, 2.5 and 16 mm³/month. The ≥50% volume increase appears to be a too sensitive marker of disease progression, with a downstream higher surgery rate. The assessment of growth rate could distinguish mPTC with high and low growth rates, which would allow us to tailor the algorithm of the evaluations to a more appropriate timing.